Concepedia

James McCloskey

JM

30

Publications

1.7K

Citations

19

H-Index

2005

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Hackensack University Medical Center

University of Chicago

Johns Hopkins University

Hackensack Meridian Health

James McCloskey is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pharmacotherapy, and oncology.

Top concepts

Publications per year

2005–2024

30

Publications

30

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi et al. · Blood · 2020 · 228 citations · Full text

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Guillermo Garcia‐Manero, Elizabeth A. Griffiths, David P. Steensma et al. · Blood · 2020 · 205 citations · Full text

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Jörge E. Cortes, Jane F. Apperley, Elza Lomaia et al. · Blood · 2021 · 185 citations · Full text

Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia

Naval Daver, Alexander E. Perl, Joseph Maly et al. · Journal of Clinical Oncology · 2022 · 179 citations · Full text

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Brian Ball, Christopher Famulare, Eytan M. Stein et al. · Blood Advances · 2020 · 127 citations · Full text

, , +15

Rows per page

1–5 of 30